PL1910370T3 - Monohydrat pirolo [1,2-b] pirazolu podstawionego pirydynochinoliną jako inhibitor tgf-beta - Google Patents

Monohydrat pirolo [1,2-b] pirazolu podstawionego pirydynochinoliną jako inhibitor tgf-beta

Info

Publication number
PL1910370T3
PL1910370T3 PL06774280T PL06774280T PL1910370T3 PL 1910370 T3 PL1910370 T3 PL 1910370T3 PL 06774280 T PL06774280 T PL 06774280T PL 06774280 T PL06774280 T PL 06774280T PL 1910370 T3 PL1910370 T3 PL 1910370T3
Authority
PL
Poland
Prior art keywords
tgf
pyridin
beta inhibitor
substituted pyrrolo
pyrazole monohydrate
Prior art date
Application number
PL06774280T
Other languages
English (en)
Polish (pl)
Inventor
Sreenivasa Reddy Mundla
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1910370T3 publication Critical patent/PL1910370T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL06774280T 2005-07-22 2006-06-29 Monohydrat pirolo [1,2-b] pirazolu podstawionego pirydynochinoliną jako inhibitor tgf-beta PL1910370T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70164105P 2005-07-22 2005-07-22
PCT/US2006/025377 WO2007018818A1 (en) 2005-07-22 2006-06-29 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
EP20060774280 EP1910370B1 (en) 2005-07-22 2006-06-29 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor

Publications (1)

Publication Number Publication Date
PL1910370T3 true PL1910370T3 (pl) 2015-09-30

Family

ID=37450942

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06774280T PL1910370T3 (pl) 2005-07-22 2006-06-29 Monohydrat pirolo [1,2-b] pirazolu podstawionego pirydynochinoliną jako inhibitor tgf-beta

Country Status (16)

Country Link
US (1) US7872020B2 (enExample)
EP (1) EP1910370B1 (enExample)
JP (1) JP5242391B2 (enExample)
BR (1) BRPI0613639A2 (enExample)
CA (1) CA2616196C (enExample)
DK (1) DK1910370T3 (enExample)
ES (1) ES2542425T3 (enExample)
HR (1) HRP20150474T1 (enExample)
HU (1) HUE025209T2 (enExample)
IL (1) IL188181A (enExample)
MX (1) MX2008001020A (enExample)
PL (1) PL1910370T3 (enExample)
PT (1) PT1910370E (enExample)
RS (1) RS53999B1 (enExample)
SI (1) SI1910370T1 (enExample)
WO (1) WO2007018818A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
CN103764655B (zh) * 2011-07-13 2017-04-12 Sk化学公司 作为alk5和/或alk4抑制剂的经2‑吡啶基取代的咪唑
US20150289795A1 (en) 2012-11-12 2015-10-15 Institució Catalana De Recerca I Estudis Avançats Methods and kits for the prognosis of colorectal cancer
CN105358677B (zh) 2013-03-14 2018-06-15 布里格海姆妇女医院公司 用于上皮干细胞扩增和培养的组合物和方法
KR102493376B1 (ko) 2014-09-03 2023-01-27 더 브리검 앤드 우먼즈 하스피털, 인크. 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017106291A1 (en) 2015-12-15 2017-06-22 Bristol-Myers Squibb Company Cxcr4 receptor antagonists
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10604528B2 (en) 2016-07-07 2020-03-31 Crystal Pharmaceutical (Suzhou) Co., Ltd. Galunisertib crystalline form, preparation method thereof and use thereof
US10906905B2 (en) 2016-10-14 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
CN110392686A (zh) 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
WO2018165979A1 (zh) * 2017-03-17 2018-09-20 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物
WO2018170724A1 (zh) 2017-03-21 2018-09-27 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶,其制备方法和药物组合物
WO2019042383A1 (zh) * 2017-08-31 2019-03-07 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) * 2018-01-12 2019-07-18 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019236766A1 (en) 2018-06-06 2019-12-12 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN115282280A (zh) * 2022-08-12 2022-11-04 中国科学技术大学 TGF-β1信号抑制剂的新用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ras抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1397364E (pt) 2001-05-24 2007-10-22 Lilly Co Eli Novos derivados de pirrole como agentes farmacêuticos
CA2506799A1 (en) * 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
UA80571C2 (en) * 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles

Also Published As

Publication number Publication date
HRP20150474T1 (xx) 2015-06-05
EP1910370A1 (en) 2008-04-16
RS53999B1 (sr) 2015-10-30
BRPI0613639A2 (pt) 2012-02-22
US7872020B2 (en) 2011-01-18
CA2616196C (en) 2012-08-21
SI1910370T1 (sl) 2015-06-30
ES2542425T3 (es) 2015-08-05
JP2009502780A (ja) 2009-01-29
PT1910370E (pt) 2015-06-30
CA2616196A1 (en) 2007-02-15
MX2008001020A (es) 2008-03-25
JP5242391B2 (ja) 2013-07-24
IL188181A (en) 2014-05-28
EP1910370B1 (en) 2015-04-22
HUE025209T2 (en) 2016-03-29
IL188181A0 (en) 2008-03-20
US20100120854A1 (en) 2010-05-13
WO2007018818A1 (en) 2007-02-15
DK1910370T3 (en) 2015-06-08

Similar Documents

Publication Publication Date Title
IL188181A0 (en) A pyridin quinolin substituted pyrrolo [1,2-b]pyrazole monohydrate as tgf-beta inhibitor
PL1904494T3 (pl) Związki imidazo[1,2-A]pirydynowe jako inhibitory VEGF-R2
EG25765A (en) Pyrido [2,3-B] pyrazine derivatives useful as herbicidal compounds
HUS1200009I1 (hu) Pirrolo[2,3-B]piridin származékok, mint protein kináz inhibitorok
IL179406A0 (en) Tetrahydro-imidazo[1,5-a] pyridin derivatives as aldosterone synthase inhibitors
SI1966202T1 (sl) S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
SI1697356T1 (sl) Pirido(2,3-d)pirimidin-2,4-diamini kot zaviralci PDE 2
SI2069336T1 (sl) Derivati piridin-4-ila kot imunomodulirna sredstva
PL2124944T3 (pl) Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy
PL1711481T5 (pl) Krystaliczny monohydrat jako inhibitor kinazy
PL1789041T3 (pl) Pochodne arylopirydyny jako inhibitory 11-beta-HSD1
IL195915A0 (en) 3-amino -imidazo[1,2-a]pyridine derivatives as sglt inhibitors
ZA200802690B (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
ZA200904440B (en) 6-Benzyl-2,3,4,7-Tetrahydro-indolo [2,3-C] quinoline compounds useful as PDE5 inhibitors
IL190456A0 (en) Pyrazolo[4,3-d]pirimidin-5-yl)derivative used as pde5 inhibitors
ZA200804104B (en) Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
ZA200608769B (en) Imidazopyridine compound
HK1138515A (en) Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
HK1099769A (en) Imidazopyridine compound
CY1116567T1 (el) ΕΝΑ ΠΥΡΙΔΙΝΟΚΙΝΟΛΙΝΟ-ΥΠΟΚΑΣΤΕΣΤΗΜΕΝΟ ΜΟΝΟΕΝΥΔΡΟ ΠΥΡΡΟΛΟ [1,2-B]ΠΥΡΑΖΟΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΤΟΥ TGF-β
HK1102588A (en) Tetrahydro-imidazo (1,5-a) pyridin derivatives as aldosterone synthase inhibitors
IL178688A0 (en) THIENO [3,2-b] PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS
HK1123051A (en) Octahydro-pyrrolo[3,4-b]pyrrole derivatives
AU2004901107A0 (en) Alkaloid formulation
GB0714815D0 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors